Scarica l'app Stockscreener
0.00
100.00%
-0.84
Dopo l'orario di chiusura:
.84
0.84
+
Salarius Pharmaceuticals Inc Borsa (SLRX) Ultime notizie
Is Salarius Pharmaceuticals Inc. (FP10) stock worth buying before Fed actionShare Buyback & Consistent Return Investment Signals - ulpravda.ru
Will Salarius Pharmaceuticals Inc. stock maintain growth storyPortfolio Performance Report & Safe Swing Trade Setup Alerts - ulpravda.ru
Profit Review: Is Salarius Pharmaceuticals Inc. stock overvalued by current metrics2025 Analyst Calls & Weekly Setup with High ROI Potential - ulpravda.ru
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikesJuly 2025 Patterns & AI Optimized Trade Strategies - ulpravda.ru
Decoy Therapeutics Inc Com Par $0.0001 (New) (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Salarius Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Risk Managed Trade Strategies - ulpravda.ru
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - TipRanks
Is Salarius Pharmaceuticals Inc. (FP10) stock a momentum leader2025 Technical Overview & Fast Exit and Entry Strategy Plans - ulpravda.ru
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals changes name to Decoy Therapeutics - MarketScreener
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Biotech rebrands as Decoy Therapeutics to pursue next-gen antivirals - Stock Titan
Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency - MSN
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius Pharmaceuticals and Decoy Therapeutics announce merger - MSN
Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded by Wall Street Zen to Sell - Defense World
Salarius Shareholders Back Directors, Executive Pay and Auditor - TipRanks
Salarius Pharmaceuticals Appeals Nasdaq Delisting After Bid Deficiency - TipRanks
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting By Investing.com - Investing.com South Africa
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals faces potential Nasdaq delisting after bid price rule breach - Investing.com
Salarius Pharmaceuticals (NASDAQ: SLRX) appeals Nasdaq delisting over $1.00 bid rule - Stock Titan
Salarius shareholders back directors, executive pay and auditor - MSN
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Can Salarius Pharmaceuticals Inc. stock hit analyst price targets2025 Valuation Update & Fast Moving Market Watchlists - Улправда
Wall Street Recap: Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targetsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - The Manila Times
Salarius Pharmaceuticals adjourns annual meeting over quorum shortfall - MSN
Investment Review: Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Fast Moving Stock Watchlists - Улправда
Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall - TipRanks
Salarius Pharmaceuticals adjourns annual meeting due to low turnout By Investing.com - Investing.com Nigeria
Can Salarius Pharmaceuticals Inc. (FP10) stock hit consensus price targets2025 EndofYear Setup & Expert Verified Stock Movement Alerts - Улправда
Salarius Pharmaceuticals adjourns annual meeting due to low turnout - Investing.com
What dividend safety rating applies to Salarius Pharmaceuticals Inc. (FP10) stockPortfolio Return Report & Fast Gain Stock Tips - DonanımHaber
What makes Salarius Pharmaceuticals Inc. stock attractive to growth fundsSwing Trade & Real-Time Stock Entry Alerts - DonanımHaber
Barbara Louise Hibner Net Worth (2025) - GuruFocus
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals to Change Name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals (SLRX) to Rebrand as Decoy Therapeutics - GuruFocus
SLRX Insider Trading - Quiver Quantitative
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):